Internal Medicine

🩸 Coagulation Disorders

Understanding Bleeding and Clotting

Amos Asamoah
October 2025
7 min read
Hematology

Coagulation disorders represent disruptions in the sophisticated hemostatic balance that maintains blood fluidity while enabling rapid clot formation at sites of vascular injury. These conditions span from inherited bleeding diatheses to acquired thrombotic tendencies, each with distinct pathophysiological mechanisms, clinical presentations, and therapeutic approaches that require precise diagnosis and targeted management strategies.

βš–οΈ Hemostasis Fundamentals

Normal hemostasis involves a precisely regulated interplay between procoagulant and anticoagulant systems, vascular integrity, platelet function, and fibrinolytic activity:

Primary Hemostasis

  • Process: Initial platelet plug formation at vascular injury sites
  • Key Components: Platelets, von Willebrand factor, vascular endothelium
  • Sequence: Vasoconstriction β†’ platelet adhesion β†’ activation β†’ aggregation
  • Laboratory Assessment: Platelet count, bleeding time, PFA-100
  • Clinical Disorders: ITP, von Willebrand disease, platelet function defects
  • Bleeding Pattern: Immediate, mucocutaneous bleeding

Secondary Hemostasis

  • Process: Fibrin clot formation via coagulation cascade
  • Key Components: Coagulation factors, tissue factor, calcium
  • Pathways: Extrinsic, intrinsic, and common coagulation pathways
  • Laboratory Assessment: PT, PTT, thrombin time, specific factor assays
  • Clinical Disorders: Hemophilia, vitamin K deficiency, liver disease
  • Bleeding Pattern: Delayed, deep tissue bleeding
🎯 Clinical Memory Aid: Primary hemostasis creates the temporary "platelet plug" (fast but weak), while secondary hemostasis builds the stable "fibrin mesh" (slow but strong). Understanding this distinction guides differential diagnosis and laboratory evaluation.

🧬 Inherited Bleeding Disorders

Genetic disorders affecting coagulation factors or platelet function present with lifelong bleeding tendencies and require comprehensive management strategies:

Disorder Genetic Defect Laboratory Findings Clinical Features Management Clinical Pearls
Hemophilia A Factor VIII deficiency (X-linked) ↑ PTT, normal PT, low FVIII activity Joint hemorrhages, muscle hematomas, delayed bleeding FVIII concentrate, DDAVP for mild cases Most common severe inherited bleeding disorder in males
Hemophilia B Factor IX deficiency (X-linked) ↑ PTT, normal PT, low FIX activity Identical to hemophilia A clinically FIX concentrate, no DDAVP response Christmas disease, 15% of hemophilia cases
von Willebrand Disease vWF quantitative/qualitative defects (AD/AR) Variable: ↑ bleeding time, ↑ PTT, low vWF activity/antigen Mucocutaneous bleeding, menorrhagia, easy bruising DDAVP, vWF concentrate, antifibrinolytics Most common inherited bleeding disorder overall
Rare Factor Deficiencies Factors II, V, VII, X, XI, XIII (AR) Variable PT/PTT abnormalities Variable bleeding severity Specific factor replacement, FFP Factor XIII deficiency causes delayed wound bleeding
🚨 Clinical Correlation: Hemophilia severity correlates with residual factor activity: severe (<1%), moderate (1-5%), mild (5-40%). Severe hemophilia causes spontaneous bleeding, while mild hemophilia typically bleeds only with trauma or surgery.

πŸ’Š Acquired Bleeding Disorders

Acquired bleeding disorders develop secondary to medical conditions, medications, nutritional deficiencies, or autoimmune processes:

Vitamin K Deficiency

  • Mechanism: Impaired Ξ³-carboxylation of factors II, VII, IX, X
  • Causes: Malabsorption, antibiotics, malnutrition, liver disease
  • Laboratory: ↑ PT (first), ↑ PTT, normal platelets
  • Treatment: Vitamin K supplementation, FFP for severe bleeding
  • Clinical: PT prolongation appears first (FVII shortest half-life)

Liver Disease

  • Mechanism: Reduced synthesis of all factors except VIII
  • Features: ↑ PT/PTT, thrombocytopenia, elevated FVIII
  • Complications: Portal hypertension, variceal bleeding, DIC
  • Treatment: Vitamin K, FFP, platelets, PCC
  • Clinical: Factor VIII elevation distinguishes from DIC

Disseminated Intravascular Coagulation

  • Mechanism: Widespread coagulation activation and consumption
  • Triggers: Sepsis, trauma, malignancy, obstetric complications
  • Laboratory: ↑ PT/PTT, ↓ platelets, ↑ D-dimer, ↓ fibrinogen
  • Treatment: Treat underlying cause, support, cautious anticoagulation
  • Clinical: Simultaneous bleeding and thrombosis
πŸ”¬ Clinical Insight: Vitamin K-dependent factors include II, VII, IX, X and proteins C, S. Remember the mnemonic "1972" (backwards: 2, 7, 9, 10) plus the natural anticoagulants protein C and S.

πŸ”„ Thrombotic Disorders

Thrombophilias represent conditions predisposing to inappropriate clot formation, with both inherited and acquired etiologies:

Disorder Pathophysiology Thrombosis Risk Laboratory Diagnosis Management Clinical Features
Factor V Leiden Activated protein C resistance 5-7Γ— increased (heterozygous) DNA mutation analysis, APC resistance assay Anticoagulation for thrombosis Most common inherited thrombophilia
Prothrombin G20210A Increased prothrombin levels 3Γ— increased DNA mutation analysis Anticoagulation for thrombosis Second most common inherited thrombophilia
Protein C/S Deficiency Reduced natural anticoagulants 7-10Γ— increased Functional/antigen assays Anticoagulation, avoid warfarin skin necrosis Warfarin-induced skin necrosis in protein C deficiency
Antithrombin Deficiency Reduced thrombin inhibition 20-50Γ— increased Functional assay Anticoagulation, AT concentrate for surgery Heparin resistance may be presenting feature
Antiphospholipid Syndrome Acquired autoantibodies High arterial/venous risk Lupus anticoagulant, anticardiolipin antibodies Long-term anticoagulation Thrombosis, pregnancy loss, thrombocytopenia
⚠️ Critical Alert: Heparin-induced thrombocytopenia (HIT) represents a medical emergency characterized by thrombocytopenia and paradoxical thrombosis 5-10 days after heparin exposure. Immediate heparin cessation and alternative anticoagulation are mandatory to prevent life-threatening complications.

πŸ” Diagnostic Laboratory Evaluation

Systematic coagulation testing provides the foundation for accurate diagnosis and guides targeted therapeutic interventions:

Screening Tests

  • PT/INR: Extrinsic and common pathways, vitamin K factors
  • PTT: Intrinsic and common pathways, heparin monitoring
  • Thrombin Time: Fibrinogen to fibrin conversion
  • Platelet Count: Quantitative platelet assessment
  • Fibrinogen: Quantitative fibrinogen level
  • D-dimer: Fibrin degradation products, DIC/VTE evaluation

Specialized Testing

  • Mixing Studies: Differentiate factor deficiencies vs. inhibitors
  • Specific Factor Assays: Quantify individual factor levels
  • vWF Studies: Antigen, activity, multimetric analysis
  • Platelet Function: Aggregation studies, PFA-100
  • Thrombophilia Testing: Genetic and functional assays
  • Antibody Detection: HIT antibodies, lupus anticoagulant
πŸ”¬ Diagnostic Algorithm: Begin with PT/PTT/platelet count. If PT prolonged β†’ consider vitamin K deficiency, liver disease, factor VII deficiency. If PTT prolonged β†’ consider hemophilia, factor inhibitors, lupus anticoagulant. If both prolonged β†’ consider common pathway defects, DIC, liver disease.

πŸ’‰ Therapeutic Management Principles

Coagulation disorder management requires targeted therapies based on specific defects, bleeding risk, and clinical context:

Therapeutic Category Agents Mechanism of Action Clinical Applications Monitoring Parameters Reversal Strategies
Factor Replacement Specific factor concentrates, FFP, PCC Replenish deficient coagulation factors Hemophilia, major bleeding, surgery Factor levels, clinical response Dose adjustment, monitoring
Platelet-Directed Platelet transfusion, DDAVP, antifibrinolytics Enhance primary hemostasis Thrombocytopenia, platelet dysfunction Platelet count, bleeding time Discontinuation, specific antagonists
Vitamin K Antagonists Warfarin Inhibit vitamin K epoxide reductase Chronic anticoagulation, mechanical valves INR Vitamin K, FFP, PCC
Direct Oral Anticoagulants Dabigatran, rivaroxaban, apixaban Direct factor Xa or thrombin inhibition VTE, atrial fibrillation, general anticoagulation Routine monitoring not required Specific reversal agents available
Heparins UFH, LMWH, fondaparinux Potentiate antithrombin activity Acute VTE, ACS, perioperative prophylaxis PTT (UFH), anti-Xa (LMWH) Protamine sulfate (partial)

🎯 Clinical Pearls & Diagnostic Approach

Effective management of coagulation disorders requires integrated clinical assessment, systematic laboratory evaluation, and targeted therapeutic interventions:

  • Bleeding history should characterize timing, severity, triggers, and family history to distinguish platelet disorders (immediate bleeding) from coagulation factor deficiencies (delayed bleeding)
  • Mixing studies distinguish factor deficiencies (correction with normal plasma) from inhibitors (no correction or progressive inhibition)
  • Thrombophilia testing should be timed appropriatelyβ€”avoid acute thrombosis, recent anticoagulation, or acute illness for accurate results
  • Anticoagulant selection should consider patient factors, indication, monitoring requirements, cost, and reversal agent availability
  • Bleeding emergency management follows the sequence: resuscitation β†’ diagnosis β†’ specific therapy β†’ ongoing monitoring
πŸ”¬ Pathology Study Tips:
  • Master the cascade: Understand intrinsic, extrinsic, and common pathways
  • Know the tests: PT/PTT patterns point to specific defects
  • Differentiate bleeding patterns: Platelet vs. coagulation disorders
  • Understand thrombophilia: Know the major inherited and acquired causes
  • Learn anticoagulants: Mechanisms, monitoring, and reversal strategies
⚠️ Critical Concept: Coagulation disorders represent disturbances in the delicate hemostatic balance. The clinical approach must integrate bleeding/thrombotic history, physical examination findings, and systematic laboratory evaluation to establish accurate diagnoses and implement targeted, evidence-based management strategies.

🌟 Comprehensive Coagulation Management

The field of coagulation disorders encompasses a sophisticated understanding of hemostatic balance, from molecular mechanisms to clinical manifestations. Mastery of these principles enables clinicians to navigate the spectrum of bleeding and thrombotic disorders, from common conditions like vitamin K deficiency to complex scenarios like DIC or thrombotic microangiopathies.

Advances in diagnostic techniques, targeted therapies, and specific reversal agents have transformed the management of coagulation disorders, improving outcomes for patients with both inherited and acquired conditions. The ongoing development of novel anticoagulants, hemophilia gene therapies, and personalized approaches promises continued evolution in this dynamic field.

The Hemostatic Balance: "Coagulation disorders teach us the profound importance of balance in biological systems. The same mechanisms that prevent fatal hemorrhage can cause devastating thrombosis when dysregulated. Mastery of this balance represents one of clinical medicine's most sophisticated challenges and rewarding achievements."

← Previous Topic: Leukemias and Lymphomas Next Topic: HIV/AIDS β†’